PHARMACEUTICALS giant Elan could have a "path to market" for a new drug that would "transform" the company by the end of this year, the company said yesterday.The company, which is best known for its multiple sclerosis drug Tysabri, should have the lates
SWISS drug maker Novartis said it's still not sure whether its new multiple sclerosis (MS) treatment contributed to a patient on the drug contracting a potentially deadly brain infection. The patient has been taking Gilenya, a drug approved for use in 20
ELAN, the €6.5bn-valued Irish drug giant headed by Kelly Martin, paid no tax in Ireland last year, according to filings.Elan boss Martin is one of the top paid chief executives in the country. Last year, he bagged a pay deal worth €9.3m. He received €2.1
IRISH drug company Elan reckons that it will have about 130,000 patients using its multiple sclerosis treatment Tysabri within the next five years, as revenues from the product continue to surge.Elan said yesterday that its revenue during the first three
The chief executive of Irish drug company Elan, Kelly Martin, has postponed his departure from the group until potentially "transformational" data from an Alzheimer's drug trial is made public later this year.Mr Martin had agreed with the Elan board back
As shares fluctuated, the pharmaceutical giant's fortunes dipped -- now the firm's balance sheet is on verge of a makeover After nine years as boss, Kelly Martin has finally succeeded in steering Irish-based pharmaceutical company Elan into the black.It'
Biogen Idec (BIIB - Analyst Report) recently announced that Health Canada... Full Article at Zacks Investment Research
5/25/2012 7:55:40 AM Pharmaceuticals giant Elan could have a "path to... Full Article at Biospace
Initial Phase-3 test results on the bapineuzumab drug — which is being developed... Full Article at Irish Examiner
ELAN BOASTS the highest revenue per employee in the industry, chairman Bob... Full Article at Irish Times
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches... Full Article at Pharmaceutical Business Review
BIIB) said Health Canada has approved updates to TYSABRI (natalizumab)... Full Article at iStockAnalyst
TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada... Full Article at PR Newswire
...* Vedolizumab remission rate as high as 44.8 pct at one year * No increased risk... Full Article at AlertNet